Lotus Pharmaceutical Co Ltd

Lotus Pharmaceutical Co Ltd has a debt-to-equity ratio of 2.35, indicating a capital structure that is significantly leveraged. The company's liquidity position is characterized by a current ratio of 1.57, suggesting it has sufficient short-term assets to cover its short-term liabilities, but its cash and equivalents amount to only TWD 314.43 million, which is far below its long-term debt of TWD 55.93 billion. This results in a negative net cash position after subtracting total debt, which is a key liquidity risk flag.

In terms of profitability, the company's return on equity (ROE) is 19.85%, which is strong and suggests efficient use of shareholders' equity to generate profits. However, its return on assets (ROA) is 4.45%, which is relatively modest and may indicate that the company is not utilizing its assets as effectively as some of its peers. The operating margin, calculated as operating income of TWD 5.83 billion on revenue of TWD 20.51 billion, is 28.44%, which is a healthy margin for a pharmaceutical company.

Geographically, Lotus Pharmaceutical's revenue is concentrated in the Asia-Pacific region, with no disclosed breakdown of revenue by segment or region in the provided data. This lack of diversification could expose the company to regional economic or regulatory risks, particularly in markets where it has a significant presence.

The company's growth trajectory is not explicitly detailed in the provided data, but its revenue of TWD 20.51 billion and net income of TWD 4.72 billion suggest a stable financial position. Analysts have provided a mean price target of TWD 360.50, with a median of TWD 341.00, indicating a generally positive outlook. However, the company's capital expenditure of TWD -4.35 billion suggests a reduction in investment in new projects or facilities, which could impact long-term growth.

The risk assessment for Lotus Pharmaceutical Co Ltd highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position is a concern, but the low dilution risk suggests that there is little immediate threat of equity dilution through new share issuance. The risk assessment also notes that the company's capital structure is heavily reliant on long-term debt, which could increase financial risk if interest rates rise or if the company's credit rating is downgraded.

Recent events and filings do not provide specific details in the provided data, but the company's financial performance and analyst estimates suggest a generally stable and positive outlook. The company's ability to maintain its operating margin and manage its debt levels will be critical to its long-term success.